Notably, in pancreatic cancer, gemcitabine efficacy necessitates p38-MAPK activation [29], while gemcitabine resistance is augmented by the activation of STAT5 [30], SRC [31,32], and STAT3 [33]. Here, STAT5B is linked to familial pancreatic carcinoma.